SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Molecular Dynamics
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Richard Haugland who wrote (138)5/16/1998 11:50:00 AM
From: Ken Ridge   of 153
 
As usual, Individual Investor has the right idea, but terrible timing.
The 5/13 update on their web site states "we maintain our sell rating."

The June issue received a week or so ago, however, rates MDYN a "buy." At the end of the year, II will again explain poor results of the Magic 25 by implying that results would be better if you factor in mid-year ratings changes, an obvious attempt to rewrite history.

In their original recommendation, II suggested ag research could easily become larger than human-genome work. If MDYN can stay in the game, they can easily profit from the battle between DuPont and Monsanto.

I've been watching for 6 months, and will look to buy in at 12 or under, as a long term holding.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News